Livdelzi’s approval was based on results from the Phase 3 RESPONSE trial, which demonstrated improvement in key biochemical markers and reduction in pruritus.
FDA grants accelerated approval to Gilead’s Ribdelzi for treatment of primary biliary cholangitis
Leave a comment
